Cargando…
Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer
Oral VRL offers easier administration, better quality of life, and cost saving. This study aimed to evaluate the treatment efficacy in terms of tumor response of the two formulations of vinorelbine (VRL, oral and IV) in combination with epirubicin (EPI); and the effect of EPI co-administration on VR...
Autores principales: | Huang, Liang, Wang, Xiaojia, Zhou, Liheng, Di, Lijun, Zheng, Hongyu, Jiang, Zefei, Wang, Yongsheng, Song, Xiangqun, Feng, Jifeng, Yu, Shiying, Liu, Yunpeng, Zheng, Hong, Shen, Kunwei, Tong, Zhongsheng, Shao, Zhimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994442/ https://www.ncbi.nlm.nih.gov/pubmed/31838561 http://dx.doi.org/10.1007/s00280-019-04000-3 |
Ejemplares similares
-
Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis
por: Pétain, Aurélie, et al.
Publicado: (2019) -
Oral vinorelbine in metastatic breast cancer
por: Conte, PF, et al.
Publicado: (2005) -
Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months
por: Huang, Ou, et al.
Publicado: (2009) -
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study
por: Serin, D, et al.
Publicado: (2005) -
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study
por: Vici, Patrizia, et al.
Publicado: (2011)